CR11272A - Enzimas de aciltranferasa de lecitina-colesterol, modificadas - Google Patents

Enzimas de aciltranferasa de lecitina-colesterol, modificadas

Info

Publication number
CR11272A
CR11272A CR11272A CR11272A CR11272A CR 11272 A CR11272 A CR 11272A CR 11272 A CR11272 A CR 11272A CR 11272 A CR11272 A CR 11272A CR 11272 A CR11272 A CR 11272A
Authority
CR
Costa Rica
Prior art keywords
cholesterol
aciltranpherase
lecitine
enzymes
modified
Prior art date
Application number
CR11272A
Other languages
English (en)
Inventor
Mingyue Zhou
Thomas Boone
David Park Meininger
Margrit Schwartz
Bei Shan
Shen Wenyan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR11272A publication Critical patent/CR11272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)

Abstract

La invencion proporciona los compuestos, las composiciones farmaceuticas y los metodos para tratar la ateroesclerosis, la enfermedad cardiaca coronaria, la trombosis y para la disminucion o prevencion de la acumulacion de colesterol en un sujeto, mediante la modificacion del polipeptido LCAT.
CR11272A 2007-07-26 2010-02-12 Enzimas de aciltranferasa de lecitina-colesterol, modificadas CR11272A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95200707P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
CR11272A true CR11272A (es) 2010-05-26

Family

ID=39864722

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11272A CR11272A (es) 2007-07-26 2010-02-12 Enzimas de aciltranferasa de lecitina-colesterol, modificadas

Country Status (25)

Country Link
US (3) US8168416B2 (es)
EP (4) EP2489731B1 (es)
JP (5) JP5643643B2 (es)
KR (1) KR20100040937A (es)
CN (1) CN101855344B (es)
AU (1) AU2008279065B2 (es)
BR (1) BRPI0814310A2 (es)
CA (1) CA2694590A1 (es)
CR (1) CR11272A (es)
CY (2) CY1114857T1 (es)
DK (2) DK2489731T3 (es)
EA (1) EA201070187A1 (es)
ES (3) ES2449483T3 (es)
HR (1) HRP20140315T1 (es)
IL (1) IL203399A0 (es)
MX (1) MX348799B (es)
MY (1) MY159075A (es)
NZ (2) NZ597885A (es)
PL (2) PL2181190T3 (es)
PT (2) PT2489731E (es)
RS (1) RS53237B (es)
SG (1) SG186016A1 (es)
SI (2) SI2489731T1 (es)
UA (1) UA103304C2 (es)
WO (1) WO2009015314A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140315T1 (hr) * 2007-07-26 2014-05-09 Amgen Inc. Modificirani enzimi lecitin-kolesterol aciltransferaze
JP5759988B2 (ja) * 2009-06-12 2015-08-05 アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ 貧血および赤血球機能不全を治療するためのｌｃａｔの使用
CN103025348B (zh) 2010-05-06 2015-09-02 阿尔法科制药有限责任公司 传递类固醇到胆甾醇酯合成组织
EP2701732B1 (en) * 2011-02-25 2017-08-30 University Of Patras Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld)
EP2704744B1 (en) 2011-05-05 2019-04-24 Wellstat ImmunoTherapeutics, LLC Complement factor b analogs and their uses
JP6635655B2 (ja) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
WO2016022547A1 (en) * 2014-08-06 2016-02-11 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
WO2016123569A2 (en) * 2015-01-29 2016-08-04 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
WO2018022511A1 (en) 2016-07-25 2018-02-01 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
JP2021501793A (ja) * 2017-11-07 2021-01-21 アルファコア ファーマ リミテッド ライアビリティ カンパニーＡｌｐｈａｃｏｒｅ Ｐｈａｒｍａ Ｌｌｃ 心疾患、心血管疾患及び関連する病状と症状を治療し保護する方法
CN112752841B (zh) * 2018-05-22 2024-04-05 帝斯曼知识产权资产管理有限公司 经修饰的甾醇酰基转移酶
US11612619B2 (en) 2018-11-01 2023-03-28 National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Compostions and methods for enabling cholesterol catabolism in human cells
US12544402B2 (en) 2020-02-28 2026-02-10 Repair Biotechnologies, Inc. Targeted expression of microbial cholesterol catalysis genes reduces excess lipid

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63167409A (ja) 1986-12-27 1988-07-11 Yamaha Corp 磁気記録体
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
JP3254219B2 (ja) 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
GEP20002029B (en) 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
ATE353957T1 (de) * 1995-11-09 2007-03-15 Us Gov Health & Human Serv Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6498019B1 (en) * 1997-04-11 2002-12-24 Takeda Chemical Industries, Ltd. Lecithin-cholesterol acyltransferase protein
ES2206868T3 (es) 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU5931600A (en) 1999-07-14 2001-02-05 Betagene, Inc. Lcat recombinant cell line compositions and methods
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
HRP20140315T1 (hr) * 2007-07-26 2014-05-09 Amgen Inc. Modificirani enzimi lecitin-kolesterol aciltransferaze

Also Published As

Publication number Publication date
ES2513716T3 (es) 2014-10-27
JP5643643B2 (ja) 2014-12-17
PT2489731E (pt) 2014-09-15
US9006408B2 (en) 2015-04-14
CY1115573T1 (el) 2017-01-04
EP2522721A2 (en) 2012-11-14
WO2009015314A3 (en) 2009-03-12
CN101855344A (zh) 2010-10-06
PL2489731T3 (pl) 2015-01-30
EP2489730A1 (en) 2012-08-22
BRPI0814310A2 (pt) 2015-01-06
SI2181190T1 (sl) 2014-04-30
NZ597885A (en) 2013-08-30
JP6033258B2 (ja) 2016-11-30
US20140287479A1 (en) 2014-09-25
MX348799B (es) 2017-06-29
PL2181190T3 (pl) 2014-06-30
HK1138039A1 (en) 2010-08-13
AU2008279065A1 (en) 2009-01-29
SG186016A1 (en) 2012-12-28
EP2522721B1 (en) 2016-05-04
WO2009015314A2 (en) 2009-01-29
JP2018161134A (ja) 2018-10-18
EA201070187A1 (ru) 2010-08-30
EP2489731B1 (en) 2014-08-27
PT2181190E (pt) 2014-02-24
IL203399A0 (en) 2011-07-31
JP2020058366A (ja) 2020-04-16
AU2008279065B2 (en) 2013-12-12
DK2181190T3 (da) 2014-03-31
UA103304C2 (ru) 2013-10-10
HRP20140315T1 (hr) 2014-05-09
RS53237B (sr) 2014-08-29
CY1114857T1 (el) 2016-12-14
NZ582794A (en) 2012-09-28
ES2449483T3 (es) 2014-03-19
EP2522721A3 (en) 2013-01-23
SI2489731T1 (sl) 2014-12-31
ES2559353T3 (es) 2016-02-11
MY159075A (en) 2016-12-15
JP2010534479A (ja) 2010-11-11
US20090081182A1 (en) 2009-03-26
EP2181190A2 (en) 2010-05-05
US8703926B1 (en) 2014-04-22
DK2489731T3 (en) 2014-11-17
CN101855344B (zh) 2015-12-09
CA2694590A1 (en) 2009-01-29
JP2016182136A (ja) 2016-10-20
EP2489730B1 (en) 2015-12-30
EP2181190B1 (en) 2014-01-08
KR20100040937A (ko) 2010-04-21
JP2014198047A (ja) 2014-10-23
EP2489731A1 (en) 2012-08-22
US8168416B2 (en) 2012-05-01

Similar Documents

Publication Publication Date Title
CR11272A (es) Enzimas de aciltranferasa de lecitina-colesterol, modificadas
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
TWI372061B (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
SG10201805670QA (en) Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
ITRM20050265A1 (it) Protesi modulare perfezionata per osteosintesi, in particolare per l'osteosintesi dell'omero.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
CY1115236T1 (el) Ενωσεις για την προληψη και τη θεραπεια των καρδιαγγειακων παθησεων
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
CR9903A (es) Compuestos antihipercolesterolemicos
AR050717A1 (es) Composiciones farmaceuticas
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
ECSP11011472A (es) Antagonistas ccr3 arilsulfonamida 2, 5- disustituídos
ECSP003707A (es) Diazepanes
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento
DE602006010852D1 (de) Proliferationshemmendes arzneimittel
EA200970293A1 (ru) Новые производные 5-тиоксилопиранозы